{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T04:11:33Z","timestamp":1742443893267,"version":"3.40.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012533","name":"Minia University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012533","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Aim<\/jats:title>\n            <jats:p>To evaluate the therapeutic effect of a single intravitreal dexamethasone implant (Ozurdex<jats:sup>\u00ae<\/jats:sup>) in eyes with refractory diabetic macular oedema (DME) anatomically via optical coherence tomography (OCT) and functionally via best corrected visual acuity (BCVA) and multifocal electroretinography (mfERG).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This prospective interventional study included twenty eyes with refractory DME that were treated using six intravitreal injections of anti-vascular endothelial growth factor (VEGF). The central retinal thickness (CRT) was measured via OCT exceeding 300\u00a0\u03bcm. The eyes were treated with a single dexamethasone (DEX) implant four weeks after the last injection of anti-VEGF. The outcomes included changes in CRT, BCVA and p1 amplitude of ring 1 on mfERG and intraocular pressure (IOP) recorded before injection and two, four and six months after DEX injection.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The study included fifteen males (75%) and five females (25%). The mean age was 62.83 \u00b1 6.34 years, with the mean duration of diabetes was 16.7 \u00b1 2.21 years. During the two-month follow-up, there were statistically significant reductions in CRT and logMAR BCVA as well as an increase in p1 of ring 1 on mfERG (<jats:italic>P<\/jats:italic>\u2009=\u20090.046, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001 and <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001, respectively). At four months, these changes were not statistically significant (<jats:italic>P<\/jats:italic>\u2009=\u20090.99, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.56&amp;<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.58), whereas at six months, all the parameters nearly reached pre-DEX injection values (<jats:italic>p<\/jats:italic>\u2009=\u20090.93 <jats:italic>P<\/jats:italic>\u2009=\u20090.99 <jats:italic>P<\/jats:italic>\u2009=\u20090.81). The IOP values were not significantly increased at two, four or six months (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.06, <jats:italic>P<\/jats:italic>\u2009=\u20090.35 and <jats:italic>P<\/jats:italic>\u2009=\u20091.0, respectively). There were significant negative correlations between the mfERG and OCT parameters before and six months after DEX injection (<jats:italic>p<\/jats:italic>\u2009=\u20090.000).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>A single intravitreal injection of DEX in refractory DME patients induced significant anatomical and functional improvements, but these improvements only lasted for short periods of up to four months. This treatment exhibited an excellent safety profile. However, at six months, the therapeutic effect was null. The utility of mfERG as a sensitive biomarker of treatment efficacy was highlighted herein.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40942-025-00652-x","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T09:16:21Z","timestamp":1742375781000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Use of a multifocal electroretinogram to evaluate the therapeutic effect of a single intravitreal dexamethasone implant, Ozurdex\u00ae, for refractory diabetic macular oedema"],"prefix":"10.1186","volume":"11","author":[{"given":"Aya Refaat Ali","family":"Mohammed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed Farouk Sayed","family":"Othman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yehia Mahmoud","family":"Khairat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amr Ahmed Mohamed","family":"Abdelrahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"issue":"1","key":"652_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ophtha.2008.09.037","volume":"116","author":"H Funatsu","year":"2009","unstructured":"Funatsu H, Noma H, Mimura T, Eguchi S, Hori S. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology. 2009;116(1):73\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2008.09.037.","journal-title":"Ophthalmology"},{"issue":"5","key":"652_CR2","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s40265-017-0704-6","volume":"77","author":"SU Shah","year":"2017","unstructured":"Shah SU, Maturi RK. Therapeutic options in refractory diabetic macular oedema. Drugs. 2017;77(5):481\u201392. https:\/\/doi.org\/10.1007\/s40265-017-0704-6.","journal-title":"Drugs"},{"issue":"3","key":"652_CR3","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1001\/jamaophthalmol.2015.5346","volume":"134","author":"SB Bressler","year":"2016","unstructured":"Bressler SB, Ayala AR, Bressler NM, Melia M, Qin H, Ferris FL III, Flaxel CJ, Friedman SM, Glassman AR, Jampol LM, et al. Persistent macular thickening after Ranibizumab treatment for diabetic macular edema with vision impairment. JAMA Ophthalmol. 2016;134(3):278\u201385. https:\/\/doi.org\/10.1001\/jamaophthalmol.2015.5346.","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"652_CR4","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1159\/000364955","volume":"232","author":"H Noma","year":"2014","unstructured":"Noma H, Mimura T, Yasuda K, Shimura M. Role of inflammation in diabetic macular edema. Ophthalmologica. 2014;232(3):127\u201335. https:\/\/doi.org\/10.1159\/000364955.","journal-title":"Ophthalmologica"},{"issue":"10","key":"652_CR5","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1016\/j.ophtha.2014.04.019","volume":"121","author":"J Cunha-Vaz","year":"2014","unstructured":"Cunha-Vaz J, Ashton P, Iezzi R, Campochiaro P, Dugel PU, Holz FG, Weber M, Danis RP, Kuppermann BD, Bailey C, et al. Sustained delivery Fluocinolone acetonide vitreous implants: Long-Term benefit in patients with chronic diabetic macular edema. Ophthalmology. 2014;121(10):1892\u2013903. https:\/\/doi.org\/10.1016\/j.ophtha.2014.04.019.","journal-title":"Ophthalmology"},{"issue":"3","key":"652_CR6","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1517\/14712598.2016.1131265","volume":"16","author":"RM Hussain","year":"2016","unstructured":"Hussain RM, Ciulla TA. Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy. Expert Opin Biol Ther. 2016;16(3):365\u201374.","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"652_CR7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.survophthal.2007.12.005","volume":"53","author":"MA Cunningham","year":"2008","unstructured":"Cunningham MA, Edelman JL, Kaushal S. Intravitreal steroids for macular edema: the past, the present, and the future. Surv Ophthalmol. 2008;53(2):139\u201349. https:\/\/doi.org\/10.1016\/j.survophthal.2007.12.005.","journal-title":"Surv Ophthalmol"},{"issue":"1","key":"652_CR8","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1167\/iovs.10-5285","volume":"52","author":"J-E Chang-Lin","year":"2011","unstructured":"Chang-Lin J-E, Attar M, Acheampong AA, Robinson MR, Whitcup SM, Kuppermann BD, Welty D. Pharmacokinetics and pharmacodynamics of a Sustained-Release dexamethasone intravitreal implant. Investig Ophthalmol Vis Sci. 2011;52(1):80\u20136. https:\/\/doi.org\/10.1167\/iovs.10-5285.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"10","key":"652_CR9","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","volume":"121","author":"DS Boyer","year":"2014","unstructured":"Boyer DS, Yoon YH, Belfort R, Bandello F, Maturi RK, Augustin AJ, Li X-Y, Cui H, Hashad Y, Whitcup SM, Three-Year. Randomized, Sham-Controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121(10):1904\u201314. https:\/\/doi.org\/10.1016\/j.ophtha.2014.04.024.","journal-title":"Ophthalmology"},{"issue":"2","key":"652_CR10","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ophtha.2017.08.031","volume":"125","author":"D Zur","year":"2018","unstructured":"Zur D, Iglicki M, Busch C, Invernizzi A, Mariussi M, Loewenstein A, Busch C, Cebeci Z, Chhablani JK, Chaikitmongkol V, et al. OCT biomarkers as functional outcome predictors in diabetic macular edema treated with dexamethasone implant. Ophthalmology. 2018;125(2):267\u201375. https:\/\/doi.org\/10.1016\/j.ophtha.2017.08.031.","journal-title":"Ophthalmology"},{"issue":"2","key":"652_CR11","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1111\/aos.14230","volume":"98","author":"D Zur","year":"2020","unstructured":"Zur D, Iglicki M, Sala-Puigdollers A, Chhablani J, Lupidi M, Fraser-Bell S, Mendes TS, Chaikitmongkol V, Cebeci Z, Dollberg D, et al. Disorganization of retinal inner layers as a biomarker in patients with diabetic macular oedema treated with dexamethasone implant. Acta Ophthalmol. 2020;98(2):e217\u201323. https:\/\/doi.org\/10.1111\/aos.14230.","journal-title":"Acta Ophthalmol"},{"issue":"7","key":"652_CR12","doi-asserted-by":"publisher","first-page":"e0200365","DOI":"10.1371\/journal.pone.0200365","volume":"13","author":"M Iglicki","year":"2018","unstructured":"Iglicki M, Lavaque A, Ozimek M, Negri HP, Okada M, Chhablani J, Busch C, Loewenstein A, Zur D. Biomarkers and predictors for functional and anatomic outcomes for small gauge Pars plana vitrectomy and peeling of the internal limiting membrane in Na\u00efve diabetic macular edema: the VITAL study. PLoS ONE. 2018;13(7):e0200365. https:\/\/doi.org\/10.1371\/journal.pone.0200365.","journal-title":"PLoS ONE"},{"issue":"11","key":"652_CR13","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.oret.2021.01.013","volume":"5","author":"F Tang","year":"2021","unstructured":"Tang F, Luenam P, Ran AR, Quadeer AA, Raman R, Sen P, Khan R, Giridhar A, Haridas S, Iglicki M, et al. Detection of diabetic retinopathy from Ultra-Widefield scanning laser ophthalmoscope images: A multicenter deep learning analysis. Ophthalmol Retina. 2021;5(11):1097\u2013106. https:\/\/doi.org\/10.1016\/j.oret.2021.01.013.","journal-title":"Ophthalmol Retina"},{"issue":"3","key":"652_CR14","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s10792-019-01215-4","volume":"40","author":"H Khojasteh","year":"2020","unstructured":"Khojasteh H, Riazi-Esfahani H, Khalili Pour E, Faghihi H, Ghassemi F, Bazvand F, Mahmoudzadeh R, Salabati M, Mirghorbani M, Riazi Esfahani M. Multifocal electroretinogram in diabetic macular edema and its correlation with different optical coherence tomography features. Int Ophthalmol. 2020;40(3):571\u201381. https:\/\/doi.org\/10.1007\/s10792-019-01215-4.","journal-title":"Int Ophthalmol"},{"issue":"2","key":"652_CR15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00281-008-0111-x","volume":"30","author":"AP Adamis","year":"2008","unstructured":"Adamis AP, Berman AJ. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol. 2008;30(2):65\u201384. https:\/\/doi.org\/10.1007\/s00281-008-0111-x.","journal-title":"Semin Immunopathol"},{"key":"652_CR16","doi-asserted-by":"crossref","unstructured":"El-Asrar AMA. Role of inflammation in the pathogenesis of diabetic retinopathy. Middle East Afr J Ophthalmol. 2012;19(1).","DOI":"10.4103\/0974-9233.92118"},{"key":"652_CR17","first-page":"1418","volume":"15","author":"AM Joussen","year":"2009","unstructured":"Joussen AM, Doehmen S, Le ML, Koizumi K, Radetzky S, Krohne TU, Poulaki V, Semkova I, Kociok N. TNF-alpha mediated apoptosis plays an important role in the development of early diabetic retinopathy and long-term histopathological alterations. Mol Vis. 2009;15:1418\u201328.","journal-title":"Mol Vis"},{"issue":"4","key":"652_CR18","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1159\/000499540","volume":"62","author":"D Zur","year":"2019","unstructured":"Zur D, Iglicki M, Loewenstein A. The role of steroids in the management of diabetic macular edema. Ophthalmic Res. 2019;62(4):231\u20136. https:\/\/doi.org\/10.1159\/000499540.","journal-title":"Ophthalmic Res"},{"key":"652_CR19","doi-asserted-by":"publisher","first-page":"Doc21","DOI":"10.3205\/oc000148","volume":"10","author":"P Rishi","year":"2020","unstructured":"Rishi P, Rishi E, Attiku Y, Dhami A, Iyer V. Real-world experience with pro re Nata dosing of intravitreal dexamethasone implant for eyes with refractory diabetic macular edema. GMS Ophthalmol Cases. 2020;10:Doc21. https:\/\/doi.org\/10.3205\/oc000148.","journal-title":"GMS Ophthalmol Cases"},{"issue":"1","key":"652_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12886-018-1022-9","volume":"19","author":"V Castro-Navarro","year":"2019","unstructured":"Castro-Navarro V, Cervera-Taulet E, Navarro-Palop C, Monferrer-Adsuara C, Hern\u00e1ndez-Bel L, Montero-Hern\u00e1ndez J. Intravitreal dexamethasone implant Ozurdex\u00ae in Na\u00efve and refractory patients with different subtypes of diabetic macular edema. BMC Ophthalmol. 2019;19(1):15. https:\/\/doi.org\/10.1186\/s12886-018-1022-9.","journal-title":"BMC Ophthalmol"},{"issue":"6","key":"652_CR21","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1136\/bjophthalmol-2019-314591","volume":"104","author":"C Mitsch","year":"2020","unstructured":"Mitsch C, Lammer J, Karst S, Scholda C, Pablik E, Schmidt-Erfurth UM. Systematic ultrastructural comparison of swept-source and full-depth spectral domain optical coherence tomography imaging of diabetic macular oedema. Br J Ophthalmol. 2020;104(6):868. https:\/\/doi.org\/10.1136\/bjophthalmol-2019-314591.","journal-title":"Br J Ophthalmol"},{"key":"652_CR22","doi-asserted-by":"publisher","unstructured":"Nal\u00e7ac\u0131 S, Akk\u0131n C. Dexamethasone implant in patients with diabetic macular edema resistant to Anti-VEGF therapy. 2019;49(2):73\u20137 https:\/\/doi.org\/10.4274\/tjo.galenos.2018.84665","DOI":"10.4274\/tjo.galenos.2018.84665"},{"issue":"12","key":"652_CR23","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1016\/j.ophtha.2014.07.002","volume":"121","author":"MC Gillies","year":"2014","unstructured":"Gillies MC, Lim LL, Campain A, Quin GJ, Salem W, Li J, Goodwin S, Aroney C, McAllister IL, Fraser-Bell S. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology. 2014;121(12):2473\u201381. https:\/\/doi.org\/10.1016\/j.ophtha.2014.07.002.","journal-title":"Ophthalmology"},{"key":"652_CR24","doi-asserted-by":"crossref","unstructured":"Malcl\u00e8s A, Dot C, Voirin N, Agard \u00c9, Vi\u00e9 A-L, Bellocq D, Denis P, Kodjikian L. Real-Life study in diabetic macular edema treated with dexamethasone implant: the reldex study. RETINA. 2017;37(4).","DOI":"10.1097\/IAE.0000000000001234"},{"key":"652_CR25","doi-asserted-by":"crossref","unstructured":"Maturi RK, Pollack A, Uy HS, Varano M, Gomes AMV, Li X-Y, Cui H, Lou J, Hashad Y, Whitcup SM et al. Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-Year Mead study. RETINA 2016;36(6).","DOI":"10.1097\/IAE.0000000000001004"},{"issue":"1","key":"652_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000492132","volume":"241","author":"P Mello Filho","year":"2018","unstructured":"Mello Filho P, Andrade G, Maia A, Maia M, Biccas Neto L, Muralha Neto A, Moura Brasil O, Minelli E, Dalloul C, Iglicki M. Effectiveness and safety of intravitreal dexamethasone implant (Ozurdex) in patients with diabetic macular edema: A Real-World experience. Ophthalmologica. 2018;241(1):9\u201316. https:\/\/doi.org\/10.1159\/000492132.","journal-title":"Ophthalmologica"},{"key":"652_CR27","doi-asserted-by":"crossref","unstructured":"Iglicki M, Busch C, Zur D, Okada M, Mariussi M, Chhablani JK, Cebeci Z, Fraser-Bell S, Chaikitmongkol V, Couturier A et al. Dexamethasone implant for diabetic macular edema in Naive compared with refractory eyes: the international retina group Real-Life 24-Month multicenter study. the Irgrel-Dex study. Retina. 2019;39(1).","DOI":"10.1097\/IAE.0000000000002196"},{"issue":"6","key":"652_CR28","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00592-018-1117-z","volume":"55","author":"M Iglicki","year":"2018","unstructured":"Iglicki M, Zur D, Busch C, Okada M, Loewenstein A. Progression of diabetic retinopathy severity after treatment with dexamethasone implant: a 24-month cohort study the \u2018DR-Pro-DEX study\u2019. Acta Diabetol. 2018;55(6):541\u20137. https:\/\/doi.org\/10.1007\/s00592-018-1117-z.","journal-title":"Acta Diabetol"},{"issue":"null","key":"652_CR29","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.2147\/OPTH.S303670","volume":"15","author":"M Al-Latayfeh","year":"2021","unstructured":"Al-Latayfeh M, Abdel Rahman M, Shatnawi R. Outcome of single dexamethasone implant injection in the treatment of persistent diabetic macular edema after Anti-VEGF treatment: Real-Life data from a tertiary hospital in Jordan. Clin Ophthalmol. 2021;15(null):1285\u201391. https:\/\/doi.org\/10.2147\/OPTH.S303670.","journal-title":"Clin Ophthalmol"},{"issue":"10","key":"652_CR30","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.oftale.2015.10.019","volume":"90","author":"L Guti\u00e9rrez-Ben\u00edtez","year":"2015","unstructured":"Guti\u00e9rrez-Ben\u00edtez L, Millan E, Arias L, Garcia P, Cobos E, Caminal M. Dexamethasone intravitreal implants for diabetic macular edema refractory to Ranibizumab monotherapy or combination therapy. Arch De La Sociedad Espa\u00f1ola De Oftalmolog\u00eda (English Edition). 2015;90(10):475\u201380. https:\/\/doi.org\/10.1016\/j.oftale.2015.10.019.","journal-title":"Arch De La Sociedad Espa\u00f1ola De Oftalmolog\u00eda (English Edition)"},{"issue":"1","key":"652_CR31","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12886-024-03341-9","volume":"24","author":"JB Moreno","year":"2024","unstructured":"Moreno JB, Medina DB, Rosell\u00f3n-Escobar MF, Garc\u00eda-Aguirre JG. Short-term effect of intravitreal dexamethasone implant in refractory diabetic macular edema. BMC Ophthalmol. 2024;24(1):113. https:\/\/doi.org\/10.1186\/s12886-024-03341-9.","journal-title":"BMC Ophthalmol"},{"issue":"null","key":"652_CR32","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.2147\/OPTH.S48364","volume":"7","author":"E Pacella","year":"2013","unstructured":"Pacella E, Vestri AR, Muscella R, Carbotti MR, Castellucci M, Coi L, Turchetti P, Pacella F. Preliminary results of an intravitreal dexamethasone implant (Ozurdex\u00ae) in patients with persistent diabetic macular edema. Clin Ophthalmol. 2013;7(null):1423\u20138. https:\/\/doi.org\/10.2147\/OPTH.S48364.","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"652_CR33","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1186\/s12886-020-01716-2","volume":"20","author":"J Zarranz-Ventura","year":"2020","unstructured":"Zarranz-Ventura J, Romero-N\u00fa\u00f1ez B, Bernal-Morales C, Velazquez-Villoria D, Sala-Puigdollers A, Figueras-Roca M, Copete S, Distefano L, Boixadera A, Garc\u00eda-Arumi J, et al. Differential response to intravitreal dexamethasone implant in Na\u00efve and previously treated diabetic macular edema eyes. BMC Ophthalmol. 2020;20(1):443. https:\/\/doi.org\/10.1186\/s12886-020-01716-2.","journal-title":"BMC Ophthalmol"},{"issue":"4","key":"652_CR34","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1177\/112067210801800417","volume":"18","author":"M Karacorlu","year":"2008","unstructured":"Karacorlu M, Ozdemir H, Senturk F, Arf Karacorlu S, Uysal O. Macular function by multifocal electroretinogram in diabetic macular edema after intravitreal triamcinolone acetonide injection. Eur J Ophthalmol. 2008;18(4):601\u20138. https:\/\/doi.org\/10.1177\/112067210801800417.","journal-title":"Eur J Ophthalmol"},{"issue":"12","key":"652_CR35","doi-asserted-by":"publisher","first-page":"e0145663","DOI":"10.1371\/journal.pone.0145663","volume":"10","author":"R Mastropasqua","year":"2016","unstructured":"Mastropasqua R, Toto L, Borrelli E, Di Antonio L, De Nicola C, Mastrocola A, Di Nicola M, Carpineto P. Morphology and function over a One-Year follow up period after intravitreal dexamethasone implant (Ozurdex) in patients with diabetic macular edema. PLoS ONE. 2016;10(12):e0145663. https:\/\/doi.org\/10.1371\/journal.pone.0145663.","journal-title":"PLoS ONE"},{"key":"652_CR36","doi-asserted-by":"crossref","unstructured":"Tranos P, Koukoula S, de Politis PB, Tranou M, Giamouridou O, Stavrakas P, Panos GD. Effects of Dexamethasone Intravitreal Implant on Multifocal Electroretinography in Diabetic Macular Oedema. Drug Design, Development and Therapy. 2024:5367\u20135375.","DOI":"10.2147\/DDDT.S477677"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00652-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-025-00652-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00652-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T09:16:27Z","timestamp":1742375787000},"score":1,"resource":{"primary":{"URL":"https:\/\/journalretinavitreous.biomedcentral.com\/articles\/10.1186\/s40942-025-00652-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["652"],"URL":"https:\/\/doi.org\/10.1186\/s40942-025-00652-x","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,19]]},"assertion":[{"value":"27 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Minia University Faculty of Medicine Research Ethical Committee (FMREC), with approval number 515-2022.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Concept to publish"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}